ES-101
- Generic Name
- ES-101
A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors
Phase 1
Withdrawn
- Conditions
- Non-small Cell Lung CancerSmall Cell Lung CancerThoracic Tumors
- Interventions
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Registration Number
- NCT04841538
A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Elpiscience Biopharma, Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT04009460
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath